ERBB2 and breast cancer: It has also been approved in the neoadjuvant setting of HER2-positive inflammatory, locally advanced, and early-stage breast cancer.60 Because of promising results, significant antitumor activity, and a safe toxicity profile associated with pertuzumab in neoadjuvant trials, it is currently under evaluation in the adjuvant setting of patients with operable HER2-positive breast cancer (NCT01358877).